⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21766164 | 1.00 | — | — | |
| SCHEMBL2305227 | 1.00 | — | — | |
| SCHEMBL147416 | 0.81 | — | — | |
| SCHEMBL588229 | 0.78 | — | — | |
| SCHEMBL16850660 | 0.78 | — | — | |
| SCHEMBL6901835 | 0.78 | — | — | |
| SCHEMBL28117365 | 0.78 | CHRM2 (0.52) | — | |
| SCHEMBL3166958 | 0.77 | — | — | |
| SCHEMBL1564755 | 0.76 | — | — | |
| SCHEMBL2485243 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340543-A1 | GPR84 ANTAGONISTS AND USES THEREOF | LIMINAL BIOSCIENCES LTD (GB) | 2025-11-06 | — | — | US | disclosed |
| US-12378229-B2 | GPR84 antagonists and uses thereof | Liminal Biosciences Limited (GB) | 2025-08-05 | — | — | US | disclosed |
| US-20240360082-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2024-10-31 | — | — | US | disclosed |
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | disclosed |
| CN-117980292-A | Substituted pyridone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20240101576-A1 | HETEROCYCLIC INHIBITORS OF EGFR AND/OR HER2, FOR USE IN THE TREATMENT OF CANCER | ANTARES THERAPEUTICS, INC. | 2024-03-28 | — | — | US | disclosed |
| CN-117321046-A | Indazole-based compounds and related methods of use | 阿维纳斯企业公司 | 2023-12-29 | — | — | CN | disclosed |
| EP-4288430-A1 | GPR84 ANTAGONISTS AND USES THEREOF | Liminal Biosciences Limited (GB) | 2023-12-13 | — | — | EP | disclosed |
| CN-116981667-A | Heterocyclic inhibitors of EGFR and/or HER2 for cancer treatment | 蝎子疗法股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116888116-A | GPR84 antagonists and uses thereof | 里米诺生物科学有限公司 | 2023-10-13 | — | — | CN | disclosed |
| WO-2007140439-A2 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007140385-A2 | THIAZOLE COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20070015782-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-18 | — | — | US | disclosed |
| US-20070015782-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-18 | — | — | US | disclosed |
| US-20070015782-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-18 | — | — | US | disclosed |
| US-20070010542-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-11 | — | — | US | disclosed |
| US-20070010542-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-11 | — | — | US | disclosed |
| US-20070010542-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-11 | — | — | US | disclosed |
| EP-0519996-A1 | IMIDAZOLES | RHONE-POULENC RORER LIMITED (GB) | 1992-12-30 | — | — | EP | disclosed |
| WO-1991013876-A1 | IMIDAZOLES | RHONE-POULENC RORER LIMITED (GB) | 1991-09-19 | — | — | WO | disclosed |